GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Total Long-Term Liabilities

KYMR (Kymera Therapeutics) Total Long-Term Liabilities : $73.09 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Kymera Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Kymera Therapeutics's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was $73.09 Mil.


Kymera Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for Kymera Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kymera Therapeutics Total Long-Term Liabilities Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial 92.67 53.73 41.64 95.10 74.65

Kymera Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.91 78.95 75.38 74.65 73.09

Kymera Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Kymera Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kymera Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Executives
Jeremy G Chadwick officer: Chief Operating Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
Ellen Chiniara officer: Chief Legal Officer 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Jared Gollob officer: Chief Medical Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Bruce N. Jacobs officer: Chief Financial Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Pamela Esposito director C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Jeffrey W. Albers director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Leigh Morgan director KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Nello Mainolfi director, officer: President and CEO C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Richard Chesworth officer: Chief Scientific Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472